Catalogue Number: 18121-IBL
|Manufacturer:||IBL - (Immuno-Biologicals Laboratories Co Ltd)|
|Physical state:||Lyophilized product from PBS containing 1 % BSA and 0.05 % NaN3|
|Type:||Polyclonal Primary Antibody - Unconjugated|
|Shipping Condition:||Blue Ice|
|Unit(s):||100 ug, 10 ug|
|Immunogen:||Synthetic peptide of the C terminal part of Human c-Ret sort isoform|
Description: The ret proto-oncogene products (c-Ret) are expressed as 150kDa and 170kDaglycoproteins in neuroblastoma cells and as 150kDa and 190kDa glycoproteins in leukemia cells. These proteins are produced from a single polypeptide of 120kDa by posttranslational glycosylation. Although expression of the ret proto-oncogene was frequently detected in human tumors such as neuroblastoma, pheochromocytoma and thyroid medullary carcinoma, its physiological function is unknown. It turned out that the extracellular domain of the c-Ret contains a cadherin-related sequence that is
known to be important for Ca2+-dependent homophilic binding of cadherins. The homologous sequence found in the c-Ret consists of about 110 amino acids and is tandemly repeated 3 – 4 times in the extracellular domains of all vertebrate cadherins. The sequence of the c-Ret showed 20-30% identity with the member of the cadherin superfamily in the amino acid level. This suggests that possibility that the c-Ret may function as a cell adhesion molecule like cadherins. This antibody specifically recognizes human c-Ret short isoform (RET9/R787).
Cross-reacts with mouse and rat.